Elephant mRNA vaccine shows first peer-reviewed protection signal

An experimental mRNA vaccine against elephant endotheliotropic herpesvirus, or EEHV, has delivered its first peer-reviewed signs of clinical protection, according to new reports from Baylor College of Medicine and Houston Zoo. In two companion Journal of Virology papers announced July 28, 2026, the teams said vaccinated young Asian elephants mounted immune responses, and two vaccinated juveniles at Cincinnati Zoo later survived natural EEHV1A infection without developing hemorrhagic disease. (houstonzoo.org)

That’s notable because EEHV has been one of the most difficult infectious disease threats in elephant medicine for years. Houston Zoo says the virus remains the leading cause of death in juvenile Asian elephants in North American zoos, while AZA’s EEHV advisory materials describe a long-running, multi-institution effort to improve detection, treatment, and prevention. The Baylor-Houston collaboration dates to 2009, after the loss of a young Houston elephant, and has since contributed to diagnostics, serology, and treatment protocols that are now used more broadly. (houstonzoo.org)

The newly reported vaccine study evaluated a multi-antigen EEHV1A mRNA product in nine Asian elephants at five institutions. According to symposium proceedings that previewed the work, the elephants were 1.5 to 7.5 years old and received an intramuscular prime dose followed by a booster three weeks later. No severe allergic or systemic reactions were observed, though some elephants developed temporary injection-site swelling. Three elephants were already seropositive before vaccination, while six were seronegative or nearly seronegative; investigators reported sustained antibody increases in seropositive elephants, and at least three of the seronegative elephants showed preliminary responses lasting more than three months. (houstonzoo.org)

The Cincinnati cases provide the clearest real-world signal so far. Two juvenile males, Sanjay and Kabir, arrived from Dublin Zoo in November 2023 and tested seronegative for EEHV1A. After plasma transfusions in June 2024 produced only temporary antibody detection, both elephants received the experimental vaccine in October 2024 and a booster in November 2024. When natural exposure followed, Sanjay became viremic in February 2025 and Kabir in March 2025, but both maintained low viral loads, had no bloodwork changes or clinical signs, and did not require aggressive treatment. Cincinnati Zoo later said both animals cleared infection and were testing negative. (eehvinfo.org)

Institutional reaction has been hopeful, but measured. Houston Zoo CEO Lisa Peterson said the findings offer “real hope” after years of work, while Baylor virologist Paul Ling said the studies provide the first published evidence that vaccination can induce protective immune responses and may prevent severe disease associated with primary infection. Cincinnati Zoo’s Michael Wenninger called the vaccine “a tremendous source of hope” for Asian elephants in zoos and in the wild. The broader zoo community also appears to be moving from trial to cautious deployment: AZA reported this week that Oklahoma City Zoo’s calf Xerxes received an EEHV vaccine on June 17, 2026. (houstonzoo.org)

Why it matters: For veterinary professionals, this is less a finished answer than a potentially important shift in the EEHV toolkit. Until now, EEHV management has largely depended on identifying vulnerable calves through serology, frequent PCR surveillance, rapid recognition of viremia, plasma support, and aggressive antiviral and supportive care. A vaccine that can safely prime seronegative juveniles before natural exposure could change preventive planning at AZA institutions and, eventually, in range-country conservation settings. It may be especially relevant during the period when maternal antibodies wane and primary infection risk rises. Still, the evidence remains early: the published protection signal comes from two naturally infected calves, and even the investigators say additional research is needed. (houstonzoo.org)

There’s also a broader pharmacology story here. This appears to be the first peer-reviewed report of mRNA vaccine administration in elephants, and it adds to a growing body of species-specific vaccine development in zoological medicine. The work has involved Baylor, Houston Zoo, Cincinnati Zoo, Fort Worth Zoo, Rosamond Gifford Zoo, Texas Children’s Hospital collaborators, and support from groups including the International Elephant Foundation. Researchers are also exploring formulation changes and a complementary subunit vaccine, suggesting the current product may be an early platform rather than the final version. (houstonzoo.org)

What to watch: The next milestones will be publication details from the two Journal of Virology papers, additional follow-up in previously vaccinated calves, whether more seronegative juveniles show durable responses, and how quickly the vaccine moves into broader use at North American elephant programs and, eventually, range-country settings. (houstonzoo.org)